GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (OTCPK:THMO) » Definitions » Capex-to-Revenue

THMO (ThermoGenesis Holdings) Capex-to-Revenue : 0.01 (As of Mar. 2024)


View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

ThermoGenesis Holdings's Capital Expenditure for the three months ended in Mar. 2024 was $-0.02 Mil. Its Revenue for the three months ended in Mar. 2024 was $2.74 Mil.

Hence, ThermoGenesis Holdings's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.01.


ThermoGenesis Holdings Capex-to-Revenue Historical Data

The historical data trend for ThermoGenesis Holdings's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Capex-to-Revenue Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - 0.01 0.04 0.18

ThermoGenesis Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.26 0.08 0.08 0.01

Competitive Comparison of ThermoGenesis Holdings's Capex-to-Revenue

For the Medical Devices subindustry, ThermoGenesis Holdings's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's Capex-to-Revenue falls into.



ThermoGenesis Holdings Capex-to-Revenue Calculation

ThermoGenesis Holdings's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1.733) / 9.445
=0.18

ThermoGenesis Holdings's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.02) / 2.737
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings  (OTCPK:THMO) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


ThermoGenesis Holdings Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings Business Description

Traded in Other Exchanges
N/A
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.
Executives
Xiaochun Xu director 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu director 2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu director 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph director MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford director 7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate director 350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble officer: Principal Accounting Officer 2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu director
Boyalife Investment Inc. 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545